Tezampanel: Additional Phase II data

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial (NGX424MIG2001) in 306 patients

Read the full 141 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE